ACE-031: Effects, Dosage and What Its Discontinued Clinical Trials Reveal About Myostatin Inhibition

ACE-031 is a soluble activin receptor decoy that blocks myostatin to drive extraordinary muscle growth. Its Phase 2 trials were discontinued for vascular safety reasons. Effects, dosage, and what the clinical data actually shows about this extreme performance compound.

Of all the compounds in Category 5 — the extreme performance peptides — ACE-031 is the one with the most directly informative human clinical data. It went through Phase 1 and Phase 2 clinical trials in human patients. It produced documented, measurable muscle mass increases in those trials. And those same trials were discontinued for safety reasons — vascular effects that revealed important biology about the risks of systemically blocking the activin receptor pathway.

That clinical history makes ACE-031 uniquely valuable to understand in this context: it provides the clearest available window into what actually happens when myostatin inhibition is applied in humans — both the extraordinary efficacy and the unexpected safety signals that terminated the program. No other compound in this category has generated comparable human data at this level of rigor.

⚠️ Important Disclaimer: ACE-031's clinical development was discontinued due to safety concerns. It is not approved by any regulatory agency for human use. This article is for educational purposes only. Do not attempt to obtain or use ACE-031 outside of a clinical trial setting.

What Is ACE-031?

ACE-031 (development name; also referenced as ACVR2B-Fc or ActRIIB-Fc) is a recombinant fusion protein developed by Acceleron Pharma. It consists of the extracellular domain of the activin receptor type IIB (ActRIIB) fused to the Fc region of human IgG1 (an antibody constant region that extends the compound's half-life in circulation).

The design concept is elegant and distinct from Follistatin 344's approach:

Follistatin 344 works by directly binding myostatin and activin molecules — a "trap" that sequesters the ligands before they can reach their receptors
ACE-031 works as a decoy receptor — it presents the same binding surface as the real activin receptor IIB, competing with the cellular receptor for myostatin, GDF-11, and activin binding. Myostatin molecules bind ACE-031 instead of the real receptor and are thus unable to activate downstream muscle-inhibitory signaling

The Fc fusion extends ACE-031's half-life to approximately 14 days — dramatically longer than peptide compounds and allowing infrequent (monthly or biweekly) subcutaneous injections. This extended half-life was designed for therapeutic convenience in the clinical setting of chronic muscle disease.

ACE-031 is more selective than Follistatin 344 — it primarily traps myostatin and GDF-11, with less activity against Activin A and B compared to Follistatin. This relative selectivity was intended to reduce off-target effects on reproductive and other activin-regulated functions — though, as the clinical trials revealed, it was not selective enough to avoid all off-target consequences.

How Does ACE-031 Work?

1. ActRIIB Decoy Receptor Mechanism

ACE-031 presents the high-affinity ligand-binding domain of ActRIIB as a circulating decoy. When myostatin or GDF-11 molecules are released from muscle or other tissues, they bind ACE-031's decoy receptor domain rather than engaging the cell surface ActRIIB receptor. The myostatin-ACE-031 complex is then cleared from circulation without triggering the SMAD2/3 signaling cascade that suppresses muscle growth.

2. Myostatin and GDF-11 Neutralization

The primary targets of ACE-031's decoy mechanism are myostatin (GDF-8) and GDF-11 — two closely related TGF-β family members that both signal through ActRIIB. GDF-11, like myostatin, inhibits muscle growth and also plays regulatory roles in other tissues. With both removed from the signaling environment, the combined inhibitory pressure on muscle growth is substantially reduced.

3. Downstream Effects on Muscle

With myostatin and GDF-11 signaling blocked, the consequences in muscle tissue are the same as described for Follistatin 344 — satellite cell disinhibition, mTOR activation, protein synthesis enhancement, and hyperplastic fiber addition through the same SMAD2/3 pathway unblocking. The magnitude of these effects is governed by the degree to which the activin receptor system is neutralized.

What the Clinical Trials Showed

ACE-031 has the most rigorously documented human clinical profile of any myostatin inhibitor — which makes its story both the most informative and the most cautionary in this category.

Phase 1 — Healthy Volunteers

The Phase 1 trial enrolled healthy adult men and women. Key findings:

ACE-031 produced dose-dependent increases in lean body mass measured by DEXA scan — confirming that myostatin inhibition through the decoy receptor mechanism genuinely increases muscle mass in healthy humans, not just in disease states
Increases in lean mass were documented within weeks of a single injection
Decreases in fat mass were also documented — consistent with the body composition effects seen in animal myostatin-null models
The compound was generally well tolerated at lower doses with acceptable short-term safety profiles

(View Phase 1 ACE-031 research on PubMed)

Phase 2 — Duchenne Muscular Dystrophy

The Phase 2 trial enrolled boys with Duchenne Muscular Dystrophy (DMD) — a severe inherited muscle disease causing progressive muscle loss. Key findings and the reason for discontinuation:

Treated patients showed meaningful increases in lean body mass and some functional improvements — confirming efficacy in the target population
However, the trial was voluntarily discontinued by Acceleron Pharma after a subset of patients developed telangiectasias — abnormal dilations of small blood vessels visible as red spots on the skin — and some experienced epistaxis (nosebleeds)
These vascular effects were attributed to ACE-031's blockade of GDF-11 and other TGF-β family members that regulate vascular development and maintenance — off-target consequences of blocking the ActRIIB signaling pathway that extended to the vasculature
The vascular effects were not life-threatening at the doses studied, but they indicated that systemic ActRIIB pathway blockade cannot be adequately separated from vascular consequences at doses sufficient to produce meaningful muscle effects

(View Phase 2 ACE-031 research on PubMed)

The Safety Signal's Implications

The vascular safety signal from ACE-031's Phase 2 trials is one of the most important data points in the entire myostatin inhibition research landscape. It establishes several critical points:

Myostatin inhibition genuinely works in humans — lean mass increases are real and measurable. The biology translates from animals to humans.
Systemic ActRIIB pathway blockade produces vascular off-target effects — the same receptor system that myostatin uses to suppress muscle growth is also used by GDF-11 and other factors to regulate vascular biology. You cannot block one without affecting the other at the doses needed for meaningful muscle effects.
This vascular risk is a class effect — it applies to any compound that broadly blocks the ActRIIB pathway, including Follistatin 344 to the extent that it inhibits GDF-11 and activin signaling. The more broadly a compound blocks TGF-β family signaling through ActRIIB, the more likely it is to produce vascular consequences.
The risk-benefit calculation that satisfied clinical researchers for a severe disease like DMD does not translate to healthy performance use — the risk that was deemed acceptable for boys losing the ability to walk would not be acceptable for healthy athletes seeking muscle gains.

Effects: What Is Documented

1. Lean Body Mass Increase — Documented in Humans

This is ACE-031's most directly documented effect and one of its most significant distinctions in this category: unlike most extreme performance compounds, human clinical trial data confirming genuine lean mass increases exists. The Phase 1 DEXA data showing dose-dependent lean mass gains in healthy adults is the closest available proxy for the performance use case.

2. Fat Mass Reduction

Phase 1 data also documented fat mass reductions alongside lean mass gains — consistent with the body composition effects seen in animal myostatin-null models and suggesting that ActRIIB pathway blockade produces favorable body recomposition through mechanisms beyond skeletal muscle anabolism.

3. Functional Muscle Improvement in Disease

In DMD patients, functional improvement alongside lean mass increases was documented — confirming that the mass gains translated to at least some functional benefit rather than being purely cosmetic changes in body composition.

4. Vascular Effects — Documented and the Reason for Discontinuation

The telangiectasia and epistaxis observed in Phase 2 are documented adverse effects, not theoretical concerns. They establish that systemic ActRIIB blockade at doses producing meaningful muscle gains has vascular consequences in humans — a finding that is directly relevant to performance use contexts.

Dosage and Protocol

Clinical trial doses are provided for reference and context. No performance use dose has been established in clinical trials. This compound is not recommended for use outside of clinical trial settings given the documented clinical safety signal and the absence of approved therapeutic use. The following is provided for educational context only.

Parameter	Clinical Trial Context (Reference Only)
Doses studied	0.1–3.0 mg/kg in Phase 1; 1–3 mg/kg in Phase 2 (DMD)
Route	Subcutaneous injection
Frequency	Every 2–4 weeks — the ~14-day half-life of the Fc fusion enables infrequent dosing
Vascular effects onset	Observed in Phase 2 at therapeutic doses; onset timeline varies by individual

Critical note on community use: Despite the Phase 2 safety signal, ACE-031 is sold by some research peptide suppliers and used in performance contexts. Anyone considering this compound should understand that the vascular effects documented in clinical trials were observed at doses intended for therapeutic use in disease — doses that overlap with the performance use range. The vascular risk is not eliminated by using lower doses; it may only be shifted in timing and severity.

ACE-031 vs. Follistatin 344: The Complete Comparison

Feature	ACE-031	Follistatin 344
Mechanism	Soluble decoy receptor — competes with ActRIIB for ligand binding	Direct ligand binding — sequesters myostatin and activins before receptor
Selectivity	Relatively more selective — myostatin + GDF-11 primary targets	Broader — myostatin + activin A + activin B + others
Half-life	~14 days (Fc fusion)	Hours-days (protein)
Human clinical data	Phase 1 + Phase 2 trials — lean mass gain confirmed; vascular safety signal documented	Gene therapy form only (different delivery, not the peptide form)
Vascular risk	Documented — telangiectasia and epistaxis in Phase 2	Theoretical from GDF-11 blockade; not confirmed in comparable human trials
Reproductive risk	Lower than Follistatin (less activin A/B inhibition)	Higher — activin A/B inhibition relevant to FSH regulation and fertility
Antibody formation risk	Present — Fc fusion is still immunogenic in some individuals	Present — anti-follistatin antibodies could neutralize endogenous follistatin
Current development status	Discontinued (Acceleron) — vascular safety	Gene therapy active; exogenous peptide use is experimental

What Happened After ACE-031's Discontinuation

Acceleron Pharma's discontinuation of ACE-031 did not end the pursuit of myostatin inhibitors for muscle disease — it redirected it. Several successor programs emerged:

Luspatercept (ACE-536) — a more selective ActRIIA ligand trap developed by Acceleron/Bristol-Myers Squibb that targets Activin A and GDF-11 differently. FDA-approved for anemia in myelodysplastic syndromes and beta-thalassemia — not muscle disease, but demonstrating that related compounds from the same program eventually achieved approval for other indications
Bimagrumab (BYM338, anti-ActRIIB antibody) — an anti-ActRIIB antibody from Novartis that reached Phase 2/3 for muscle diseases and has been investigated for obesity, showing promising body composition results. Its clinical program was paused for different reasons but illustrates ongoing industry interest in this pathway.
Multiple specific anti-myostatin antibodies (avoiding the broader ActRIIB pathway inhibition) have entered clinical trials for muscular dystrophies, sarcopenia, and cachexia — attempting to achieve the muscle benefit with fewer off-target TGF-β family effects

The field is active, and the lesson from ACE-031 has been applied to design more selective compounds. The broad ActRIIB decoy approach was too blunt an instrument; more targeted myostatin-specific inhibition remains under active clinical development.

Side Effects and Safety Considerations

Documented From Clinical Trials

Telangiectasia — abnormal small blood vessel dilations, appearing as red spots on skin; documented in Phase 2 DMD trial; mechanism involves GDF-11 and TGF-β signaling disruption in vascular endothelium
Epistaxis (nosebleeds) — attributed to vascular fragility from the same pathway disruption
Injection site reactions — redness, swelling; common with subcutaneous protein administration
Headache — reported in Phase 1 and Phase 2
Gum bleeding — reported in some Phase 2 participants; consistent with the vascular fragility mechanism

Theoretical but Mechanism-Grounded Risks

Vascular complications beyond cosmetic telangiectasia — if GDF-11 pathway disruption is severe enough, vascular structural integrity could be affected beyond visible telangiectasia. The Phase 2 doses were therapeutic; higher performance-use doses could produce more severe vascular effects
Cancer risk — GDF-11 has established roles as a growth suppressor in some tissue types. Neutralizing it alongside myostatin removes two growth-suppressive signals simultaneously
Immunogenicity — the Fc fusion protein is immunogenic; anti-drug antibodies can develop, neutralizing the compound's activity and potentially triggering immune reactions

Frequently Asked Questions

Is ACE-031 available to buy?

Some research peptide suppliers list ACE-031 for sale, but authentic ACE-031 — the specific Acceleron Pharma recombinant ActRIIB-Fc fusion protein — is a complex biologic that requires sophisticated manufacturing processes. Products sold as "ACE-031" by unregulated peptide vendors are extremely unlikely to be the actual compound and should be treated with significant skepticism about composition and purity. This is a more acute product quality concern than for simpler peptides in this series.

Were the vascular effects from ACE-031 reversible?

In the DMD trials, the telangiectasias observed were generally described as not immediately life-threatening, and the trial was discontinued as a precaution rather than due to acute serious adverse events. Whether the vascular changes fully reversed after discontinuation is not definitively reported in the published literature. Telangiectasias from other causes — such as those associated with hereditary hemorrhagic telangiectasia (the genetic condition involving similar vessel abnormalities from TGF-β pathway mutations) — are generally persistent rather than reversible.

Why did muscle disease researchers continue pursuing myostatin inhibitors after ACE-031?

Because the efficacy signal — genuine muscle mass increases in humans — was documented and compelling for patient populations with devastating progressive muscle loss. The risk-benefit calculation for DMD or ALS patients facing wheelchair dependence and respiratory failure is fundamentally different from healthy athletes. More selective, less vascularly disruptive approaches continued development precisely because the efficacy of the mechanism was confirmed even as ACE-031 itself was discontinued.

Is ACE-031 more effective than Follistatin 344?

Direct comparison is not straightforward. ACE-031 is more selective — it primarily targets myostatin and GDF-11, while Follistatin 344 neutralizes a broader range of TGF-β family members. This broader inhibition by Follistatin makes it potentially more potent for muscle growth (more inhibitory signals removed) but also more likely to produce reproductive and vascular off-target effects. ACE-031's narrower target range may produce slightly less peak muscle growth per dose but with a somewhat more contained off-target risk profile — though the vascular signal demonstrates that "more contained" does not mean "safe."

Can the vascular effects of ACE-031 be managed?

The clinical trials did not establish a dose below which vascular effects are fully absent while above which meaningful muscle effects are achieved. The safety signal emerged at therapeutic doses — suggesting that the therapeutic window between "enough inhibition for meaningful muscle effects" and "vascular effects" may be narrow or absent for the ACE-031 mechanism. This is the fundamental challenge the field is trying to solve through more selective approaches.

Where to Learn More

For research-based posts on every major performance and muscle-building peptide — from ACE-031 and Follistatin 344 to IGF-1 LR3, PEG-MGF, and DES IGF-1 — visit our resource library.

The Bottom Line

ACE-031's clinical history is the most instructive data point in this entire category — more informative in some ways than the more dramatic animal research, because it confirms what happens in actual human biology when ActRIIB signaling is blocked systemically at doses sufficient to drive meaningful muscle growth.

The conclusion is not that myostatin inhibition doesn't work in humans — it does, and the lean mass data proves it. The conclusion is that systemic blockade of the ActRIIB pathway at effective doses produces vascular consequences that current molecular designs cannot fully separate from the muscle effects. The next generation of more selective myostatin-specific inhibitors is attempting to solve this problem — and some may succeed. The current generation, including ACE-031 and Follistatin 344, has not solved it yet.

This concludes Category 5: Hypertrophy and Extreme Performance. The final section of this series covers Category 6 — Aesthetics and Sexual Health, beginning with Melanotan II — the tanning peptide that also suppresses appetite and affects sexual function. Stay tuned.

Peptides Information

HOME

Friday, March 20, 2026